Last updated: September 9, 2026
Alferon N Injection, the brand name for interferon alfa-n3, has limited current commercial value despite FDA approval. The biologic was approved for refractory or recurring external genital warts in adults, but manufacturing interruptions, weak product differentiation, a narrow indication, and competition from procedural and generic therapies have constrained sales. Public filings do not report material standalone revenue for Alferon N Injection, and the product has not developed into a significant commercial franchise.
What is Alferon N Injection and what is it approved to treat?
Alferon N Injection is a natural alpha interferon product derived from human leukocytes. Its active ingredient is interferon alfa-n3, a mixture of naturally occurring human alpha interferon subtypes.
The FDA approved Alferon N Injection for the treatment of refractory or recurring external genital warts in adults. The product is administered by intralesional injection, which requires a healthcare professional and limits use to a relatively narrow patient population. The FDA-approved indication does not cover systemic viral infections, cancer broadly, or COVID-19-related uses that have been investigated for other interferon products.[1]
| Product characteristic |
Alferon N Injection |
| Active ingredient |
Interferon alfa-n3 |
| Product type |
Natural human leukocyte-derived interferon |
| Dosage form |
Injectable biologic |
| Administration |
Intralesional injection |
| FDA indication |
Refractory or recurring external genital warts in adults |
| Original developer |
Interferon Sciences, Inc. |
| Current commercial sponsor |
AIM ImmunoTech, through successor rights and corporate transactions |
| Primary market |
United States |
| Commercial position |
Limited or inactive commercial availability |
What is the FDA and Orange Book status of Alferon N Injection?
Alferon N Injection has an FDA approval history, but approval does not establish active commercial marketing. The product’s commercial status has been affected by manufacturing and supply problems.
FDA approval was granted through an original biologics application pathway before the modern biologics regulatory framework was fully implemented. The product is associated with FDA approval records for interferon alfa-n3 and appears in historical FDA product databases and labeling materials.[1][2]
The practical regulatory position is:
- Alferon N Injection retains historical FDA approval for its genital-warts indication.
- Commercial availability has been inconsistent.
- The product has not achieved the regulatory and commercial scale associated with leading interferon brands.
- The product does not have the market reach of pegylated interferon products or newer immunotherapies.
The Orange Book is primarily structured around approved drug products and patent certifications for small-molecule applications. Biologic products approved under the biologics framework are generally evaluated through the Purple Book and the Biologics Price Competition and Innovation Act framework rather than relying solely on Orange Book listings.[3]
Because Alferon N Injection is an older biologic product and because its regulatory pathway predates the current biosimilar system, its exclusivity analysis is more complicated than a conventional small-molecule product.
When did Alferon N Injection lose exclusivity?
Alferon N Injection does not have a meaningful remaining period of new-product regulatory exclusivity. The product was approved decades ago, and any original approval-based exclusivity has expired.
The principal commercial barriers are not statutory exclusivity periods. They are:
- manufacturing complexity;
- availability of qualified leukocyte-derived starting material;
- limited demand;
- the need for specialized intralesional administration;
- competition from lower-cost generic and procedural treatments;
- lack of a broad reimbursed market.
No commercially significant, publicly reported patent estate appears to protect a long-term market monopoly for the core interferon alfa-n3 molecule. The active ingredient is an older biologic mixture rather than a newly engineered molecule with a modern composition-of-matter patent.
What patents protect Alferon N Injection?
The commercial protection for Alferon N Injection has historically depended more on manufacturing know-how, biologic production controls, regulatory approvals, and trade secrets than on a broad blocking patent covering interferon alfa-n3 itself.
Publicly available company disclosures identify intellectual property relating to interferon products and production processes, but they do not establish a current, commercially meaningful patent barrier that would prevent competing interferon products from entering the relevant therapeutic market.[4]
| Protection category |
Current importance |
| Core molecule patent |
Low |
| Use patent for genital warts |
Limited and likely expired or commercially weak |
| Formulation patent |
No clearly material current barrier identified |
| Manufacturing know-how |
Potentially important |
| Cell or leukocyte sourcing |
Potentially important |
| Regulatory approval |
Historical value, but not market exclusivity |
| Brand recognition |
Low relative to major interferon franchises |
Why has Alferon N Injection had weak commercial performance?
Alferon N Injection competes in a treatment category with several structural disadvantages.
First, external genital warts are commonly managed with office-based procedures, topical therapies, cryotherapy, excision, electrosurgery, or other locally administered treatments. Clinicians have many alternatives that do not require a specialized biologic product.
Second, the product is used for refractory or recurring disease rather than the entire genital-warts population. That limits the addressable market.
Third, intralesional administration produces operational friction. Providers must diagnose the lesion, prepare the product, inject individual lesions, and manage repeat treatment. Payers may favor less expensive topical or procedural options.
Fourth, Alferon N Injection is not interchangeable with the better-known systemic or pegylated interferons used in hepatitis and oncology. Its indication is narrower, and its natural interferon composition does not provide a clear commercial advantage over established care pathways.
Fifth, supply interruptions damage prescribing behavior. Physicians are unlikely to build a treatment protocol around a product with uncertain availability.
What manufacturing barriers affect Alferon N Injection?
The product’s manufacturing model creates risks that do not apply to recombinant proteins produced in established microbial or mammalian cell systems.
Natural leukocyte-derived interferon requires:
- collection and qualification of human leukocytes;
- controlled induction of interferon production;
- purification of a mixture of interferon subtypes;
- viral safety controls;
- lot consistency testing;
- validated biologic manufacturing facilities.
These requirements can increase cost and complicate scale-up. They also make the product vulnerable to raw-material and facility constraints.
A recombinant interferon can be produced from a defined engineered cell line. Alferon N Injection instead relies on a biological source with greater supply-chain and batch-consistency complexity. That difference is commercially important because the product has a narrow market and cannot easily absorb high fixed manufacturing costs.
Who owns or commercializes Alferon N Injection?
Interferon Sciences originally developed and commercialized Alferon N Injection. The company later became associated with Hemispherx Biopharma through corporate transactions and rights transfers. Hemispherx subsequently changed its name to AIM ImmunoTech.[4][5]
AIM’s public disclosures describe Alferon N Injection as an FDA-approved product and identify the product as part of the company’s historical commercial portfolio. The company’s principal corporate focus has shifted toward Ampligen, also known as rintatolimod, rather than Alferon N Injection.[5]
No major pharmaceutical company has publicly disclosed a large licensing transaction or strategic commercialization deal that would indicate significant current interest in Alferon N Injection.
What is the financial trajectory of Alferon N Injection?
Alferon N Injection does not have a separately disclosed public revenue stream in recent company filings. AIM ImmunoTech reports corporate revenue, expenses, operating losses, research activity, and financing events, but public filings do not establish a material, recurring revenue contribution from Alferon N Injection.[5]
The financial trajectory is therefore best characterized as:
| Period |
Financial and commercial condition |
| Initial commercialization |
Limited specialty-product revenue |
| Manufacturing disruption period |
Reduced or suspended sales |
| Post-disruption period |
No demonstrated return to material recurring revenue |
| Recent public-company period |
Product remains a legacy asset rather than a principal revenue driver |
| Current investment relevance |
Option value is higher than demonstrated revenue value |
The company’s financial performance has been driven primarily by operating expenses, research programs, financing activity, and development-stage assets. Alferon N Injection has not been reported as a major source of sales or cash generation.[5]
What revenue exposure does Alferon N Injection represent?
The available public record does not support a material revenue valuation for Alferon N Injection. Its value is constrained by:
- a narrow FDA indication;
- uncertain commercial availability;
- lack of a broad patent moat;
- limited physician adoption;
- competition from established procedural care;
- absence of disclosed strategic commercialization investment.
Any valuation should treat Alferon N Injection as a legacy or contingent asset rather than as a platform product with predictable recurring sales.
What generic and biosimilar entry risks exist?
Traditional generic entry is less straightforward because Alferon N Injection is a biologic product rather than a conventional small-molecule drug. A competing manufacturer could pursue a biologics license application, a biosimilar pathway where legally available, or an independent approval route.
The commercial risk from competition is still high because the product has little effective exclusivity. Potential competitors could include:
- recombinant interferon products used off-label or in adjacent indications;
- other interferon formulations;
- locally administered therapies for genital warts;
- generic topical agents;
- office-based destructive procedures.
A biosimilar would not need to defeat a strong current composition-of-matter patent if no such active barrier exists. Its main challenges would be clinical comparability, manufacturing validation, market access, and sufficient demand to justify development costs.
Which companies are challenging Alferon N Injection?
No major public Paragraph IV litigation campaign against Alferon N Injection is evident. Paragraph IV litigation is primarily associated with abbreviated new drug applications for small-molecule products listed in the Orange Book. Alferon N Injection’s biologic status makes a conventional Paragraph IV generic challenge less likely.
The more relevant competitive threats are indirect. Providers can use alternative treatments without challenging Alferon N Injection’s patents. That weakens the commercial value of patent enforcement because market substitution may occur without formal litigation.
No significant publicly reported patent settlement agreement involving Alferon N Injection has established a negotiated generic or biosimilar entry date.
How strong is the patent estate for Alferon N Injection?
The patent estate appears weak as a current commercial defense.
Its strongest potential protection is process-related intellectual property covering purification, production, formulation, or quality control. Process patents can be difficult to enforce against a competitor that uses a different manufacturing method. They also do not prevent physicians from using alternative interferon products or non-interferon treatments.
The estate’s weaknesses include:
- no evident active composition-of-matter monopoly;
- an old approval date;
- a narrow indication;
- limited evidence of active continuation patenting;
- substantial non-patent competition;
- limited commercial demand.
From an investment or licensing perspective, manufacturing know-how may have more value than expired or narrow therapeutic-use patents.
What generic launch scenarios exist for Alferon N Injection?
Three launch scenarios are commercially plausible.
Scenario 1: No meaningful competitor launch
This is the most likely outcome if the market remains too small to justify development and manufacturing investment. Alferon N Injection would remain commercially marginal.
Scenario 2: Independent interferon competitor
A company with existing interferon manufacturing capability could pursue a competing product or expand an adjacent product into a relevant indication. This would increase price and supply pressure without requiring a conventional generic launch.
Scenario 3: Product reactivation by the rights holder
AIM or a partner could attempt to restore manufacturing and commercial distribution. The investment case would depend on validated supply, payer coverage, physician demand, and a differentiated use in refractory genital warts. Public filings do not show that Alferon N Injection has become a material growth program.
How does Alferon N Injection compare with competing therapies?
| Treatment category |
Commercial advantage over Alferon N |
| Cryotherapy and surgical removal |
Immediate office-based lesion treatment |
| Topical therapies |
Lower administration burden and broader routine use |
| Other local treatments |
Established clinical workflows |
| Recombinant interferons |
More standardized manufacturing |
| Pegylated interferons |
Broader historical clinical recognition, though different indications |
| Alferon N Injection |
Potential value in selected refractory or recurrent cases |
Alferon N Injection’s clinical niche is narrow. Its competitive rationale depends on patients who have failed or relapsed after more accessible treatments, but that population may be too small to support a large commercial infrastructure.
What patent litigation affects Alferon N Injection?
No major active patent litigation or settlement involving Alferon N Injection is publicly established as a principal commercial event. The absence of litigation is consistent with the product’s limited sales, old approval history, and weak generic-injunction economics.
The key legal risks are more likely to involve:
- ownership of legacy intellectual property;
- manufacturing rights;
- license scope;
- regulatory obligations;
- product liability;
- contractual disputes over commercialization.
Key Takeaways
- Alferon N Injection is interferon alfa-n3, a natural human leukocyte-derived interferon.
- The FDA-approved indication is refractory or recurring external genital warts in adults.
- The product’s original regulatory exclusivity has expired.
- No strong current composition-of-matter patent barrier is evident.
- Manufacturing complexity and supply interruptions have been central commercial constraints.
- Public filings do not show material standalone revenue from Alferon N Injection.
- AIM ImmunoTech’s financial trajectory is driven primarily by broader corporate research and financing activity, not by Alferon N sales.
- Conventional Paragraph IV litigation and biosimilar competition are less important than indirect substitution by topical therapies and office procedures.
- The product is best valued as a legacy or contingent asset rather than a high-growth biologic franchise.
FAQs
Is Alferon N Injection still available in the United States?
Commercial availability has been limited and inconsistent. Historical FDA approval does not mean that the product is continuously manufactured or distributed.
Is Alferon N Injection interchangeable with interferon alfa-2b?
No. Interferon alfa-n3 is a distinct natural interferon product and is not automatically interchangeable with interferon alfa-2b or pegylated interferon products.
Does Alferon N Injection have biosimilar competition?
No significant publicly established biosimilar competitor has become a material commercial threat. The product’s main competitive pressure comes from alternative genital-wart treatments.
Is Alferon N Injection a major revenue source for AIM ImmunoTech?
Public filings do not identify Alferon N Injection as a material recurring revenue source. AIM’s financial profile is primarily linked to development programs, operating costs, and financing activity.
Could Alferon N Injection regain commercial value?
A recovery would require reliable manufacturing, a commercialization partner, payer support, and evidence that refractory genital-wart treatment generates sufficient demand. The public record does not show a current large-scale commercial relaunch.
References
- U.S. Food and Drug Administration. (n.d.). Alferon N Injection prescribing information and product information.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA and biologics product records.
- U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products.
- AIM ImmunoTech Inc. (2024). Annual report on Form 10-K. U.S. Securities and Exchange Commission.
- AIM ImmunoTech Inc. (2023). Annual report on Form 10-K. U.S. Securities and Exchange Commission.
